Congress Reports

ESHonline Coverage, based on selected sessions at the:
American Heart Association 2004 Annual Scientific Sessions
November 7 - 10, 2004, New Orleans, Louisiana

This activity is not sanctioned by, nor a part of, the Americann Heart Association.



 
 

RIO-NA Confirms RIO-Europe and RIO-Lipids Results

November 9, 2004 (eshonline.org) – The Rimonabant in North America (RIO-NA) trial showed that the investigational cannabinoid type 1 receptor reduced body weight and waist circumference and significantly reduced central adiposity. Unlike previously studied weight-loss medications, with rimonabant the improvements were maintained at 2 years. Further, HDL-cholesterol was significantly increased, triglycerides reduced, and insulin sensitivity improved. These improvements were independent of the weight loss.

RIO-NA randomized 3040 patients (45 years old on average, 81% female, baseline BMI 37.5 kg/m2 or 27 kg/m2 plus at least 1 cardiovascular risk factor) to 5 mg rimonabant, 20 mg rimonabant, or placebo. Patients with diabetes were excluded from the study. Notably, in the 20 mg rimonabant group the percentage with metabolic syndrome was reduced at 2 years compared to placebo (22.5% compared to 34.8%).

 
The materials presented here were prepared by independent authors under the editorial supervision of ESHonline, and do not represent a publication of the American Heart Association. These materials and the related activity are not sanctioned by the American Heart Association and do not constitute an official part of that conference. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © ESHonline.org.